Completed PHASE1 INTERVENTIONAL 1-arm NCT01652794

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer

Sponsor: Case Comprehensive Cancer Center

Conditions Leydig Cell Tumor Ovarian Sarcoma Ovarian Stromal Cancer Pseudomyxoma Peritonei Recurrent Cervical Cancer Recurrent Endometrial Carcinoma Recurrent Fallopian Tube Cancer Recurrent Ovarian Epithelial Cancer Recurrent Ovarian Germ Cell Tumor Recurrent Primary Peritoneal Cavity Cancer Recurrent Uterine Sarcoma Recurrent Vaginal Cancer Recurrent Vulvar Cancer

Interventions carboplatin gemcitabine hydrochloride laboratory biomarker analysis pharmacogenomic studies stereotactic body radiation therapy

Updated 5 times since 2017 Last updated: Aug 3, 2015 Started: May 31, 2012 Primary completion: May 31, 2014 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Leydig Cell Tumor and Ovarian Sarcoma, this trial is completed. The trial is conducted by Case Comprehensive Cancer Center and has accumulated 5 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States